Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Treatment of Moderate to Severe Ulcerative Colitis With Vedolizumab and Upadacitinib
NCT06095596Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of upadacitinib in ulcerative colitis (UC) (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Endoscopic Remission Rate at 8 weeks. Started Nov 2023; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06095596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095596.